stockrowLakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- +198.9%
- Free cash flow
- +18.2%
Quarter to June 2026, against a year earlier
Follow LKFT
Alert me
Lakefront Biotherapeutics - Sponsored ADR (LKFT) Operating cash flow
Lakefront Biotherapeutics - Sponsored ADR's operating cash flow for fiscal 2025 was −$291.3M, compared with −$346.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$508.0M. Over the past ten years it has ranged from −$596.1M (fiscal 2021) to $3.6B (fiscal 2019); the current reading is higher than 55% of that period. Operating cash flow has risen for 4 consecutive fiscal years. Lakefront Biotherapeutics - Sponsored ADR ranks 597th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$291.3M | — |
| FY2024 | −$346.3M | — |
| FY2023 | −$439.4M | — |
| FY2022 | −$527.4M | — |
| FY2021 | −$596.1M | — |
| FY2020 | −$488.1M | — |
| FY2019 | $3.6B | — |
| FY2018 | −$168.3M | — |
| FY2017 | −$166.2M | — |
| FY2016 | $264.9M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$39.0M | — |
| Mar 2026 | −$96.9M | — |
| Sep 2025 | −$245.5M | — |
| Jun 2025 | −$126.6M | — |
| 33 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $177.2M |
| SEPN Septerna, Inc. compare | $106.0M |
| VCEL Vericel Corporation compare | $65.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$36.5M |
| ZYME Zymeworks Inc. compare | −$119.3M |
| IMNM Immunome, Inc. compare | −$208.8M |
| VERA Vera Therapeutics, Inc. compare | −$338.7M |
| BHVN Biohaven Ltd. compare | −$472.5M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | −$508.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on LKFT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement